Clinical Trial Update: AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD) [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability trial update for AZD2423 in patients with moderate to severe chronic obstructive pulmonary disease; the study has been completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• AZD2423

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease, Lung Disease | Phase 2 | Status: COMPLETED | Results posted: 2014-10-23